Aptamer TET-HeR of tetracycline and application thereof

By splitting and heterologously recombining tetracycline aptamers, key recognition sites are extracted to form TET-HeR, which solves the problem of insufficient affinity in tetracycline detection, achieves high affinity and specificity detection, and reduces costs.

CN120866331AActive Publication Date: 2025-10-31OCEAN UNIV OF CHINA
5 Cites 1 Cited by

Patent Information

Application Number
CN202511383082.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-09-26
Publication Date
2025-10-31
Estimated Expiration
2045-09-26

AI Technical Summary

Technical Problem

The affinity of tetracycline nucleic acid aptamers in existing technologies is insufficient, resulting in insufficient specificity of tetracycline detection and problems with antibiotic resistance and toxicity.

Method used

By splitting and heterologously recombinating multiple tetracycline aptamers, key recognition sites are extracted to form the heterologous recombination aptamer TET-HeR. Combined with optimized three-dimensional conformation and elimination of redundant sequences, high affinity and specificity detection are achieved.

Benefits of technology

This approach achieves high affinity and specificity for tetracycline detection, reduces synthesis costs, avoids cross-reactions, and provides a new pathway for nucleic acid aptamer modification.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a nucleic acid aptamer TET-HeR of tetracycline and application of the nucleic acid aptamer TET-HeR, and belongs to the technical field of nucleic acid aptamers. The nucleic acid aptamer TET-HeR of the tetracycline is a combination of an aptamer TET-A1 and an aptamer TET-C1, the nucleotide sequence of the aptamer TET-A1 is as shown in SEQ ID NO.5, and the nucleotide sequence of the aptamer TET-C1 is as shown in SEQ ID NO.7. The nucleic acid aptamer TET-HeR of the tetracycline is a combination of the aptamer TET-A1 and the aptamer TET-C1. The invention further discloses the application of the nucleic acid aptamer TET-HeR of the tetracycline in detection of the tetracycline. The affinity and dissociation constant of the nucleic acid aptamer TET-HeR of the tetracycline and the tetracycline is 62.7 nM, and the nucleic acid aptamer TET-HeR of the tetracycline has high affinity; the compound has no obvious affinity to tetracycline analogues such as aureomycin and doxycycline, has weak affinity to oxytetracycline, and has good specificity; the method can be used for specific detection of tetracycline.
Need to check novelty before this filing date? Find Prior Art